Prostate Cancer Medicine is Now Available for One-Third of the Price in India

Highlights:

Prostate cancer typically affects men over the age of 65 in India. However, there has been an increase in cancer reports among men aged 35-44 and 55-64, primarily in metropolitan areas
In India, the first generic version of Apalutamide, a medicine used to treat prostate cancer, has been introduced at one-third the original price
Apalutamide combined with androgen-deprivation treatment significantly reduced the risk of disease progression and mortality by 35%

BDR Pharmaceutical launched Apatide, the first generic of a major prostate cancer medicine - Apalutamide - in India at one-third the price of the original brand.

Biochemical Recurrence of Prostate Cancer
Biochemical recurrence (BCR) of prostate cancer is a condition that occurs in men who have previously been cured of prostate cancer. In BCR, prostate-specific antigen (PSA) is elevated above normal.

‘BDR Pharma’s prostate cancer medicine costs one-third the price of the original brand. A bottle of 60 tablets costs Rs 22,500, while a bottle of 120 tablets costs Rs 45,000.’

Pricing of Newly Launched Prostate Cancer Medicine

According to Raheel Shah, Director of Business Development, BDR Group, the medicine will be offered in India in strengths of 60mg in packs of 60 and 120 tablets. "Typically, a patient is put on this medicine for two months with a one-week break in between," Shah explained.

A bottle of 60 tablets costs Rs 22,500, while a bottle of 120 tablets costs Rs 45,000.

Brachytherapy for Prostate Cancer - Doses, Side Effects, Precautions
Learn about two different types of brachytherapy used for treating prostate cancer. Get information on the latest advances in the field.

Apalutamide and Anti-Androgen Therapy for Prostate Cancer

The University of California system invented apalutamide, which was principally developed by Janssen Research & Development, a branch of Johnson & Johnson.

“Apalutamide in combination with anti-androgen therapy will significantly improve chances for survival within metastatic castration sensitive prostate cancer patients. Apalutamide plus ADT (androgen-deprivation therapy) arm shows a significant decrease in the risk of disease progression and reduces the risk of mortality by 35% amongst Non-Metastatic Castration-resistant Prostrate Cancer,” the company said.

Decipher Test for Prostate Cancer - Indications, Procedure & Results
Decipher test a genomic test for prostate cancer that determines the aggressiveness of the cancer and helps in planning the treatment course for the cancer.

BDR Pharmaceutical’s Medicines for Prostate Cancer

The voyage of BDRs for the treatment of prostate cancer began with Abiratarone Acetate, then Leuprolide Acetate, Enzalutamide, Degarelix, and Triptorelin.

Drugs for Prostate Cancer - Treatment, Side Effects & Precautions
Prostate cancer is the main cause of cancer death in men. One of the treatment method includes prescribing chemotherapeutic or hormonal drugs. These are prescribed depending on the type and stage of cancer.

Rise in Prostate Cancer Cases Globally

Because of population increase and aging, the worldwide prostate cancer burden is anticipated to rise to 1.7 million new cases and 4, 99,000 new deaths by 2030. Prostate cancer is the second most prevalent cause of cancer in India and the sixth main cause of cancer deaths among males worldwide. People’s access to information about the disease is at a bare minimum, with minimal acceptance.

Source-Medindia